Filing identity and reporting period
Important identity mismatch: The supplied filing is Aquinox Pharmaceuticals, Inc.’s Form 10-Q for the quarter ended June 30, 2016—not a Neurogene Inc. filing. The summary below describes the filing provided. Financial amounts are in U.S. dollars unless noted.
Business context and financial results
Aquinox was a clinical-stage pharmaceutical company developing AQX-1125, a SHIP1 activator, with its lead development program focused on interstitial cystitis/bladder pain syndrome (IC/BPS). The company reported no revenue.
| Metric | Three months ended June 30, 2016 | Six months ended June 30, 2016 | Comparable 2015 period |
|---|---|---|---|
| Research and development expense | $9.235 million | $14.116 million | $3.619 million quarter; $8.186 million half-year |
| General and administrative expense | $1.830 million | $3.783 million | $1.173 million quarter; $2.646 million half-year |
| Total operating expenses | $11.065 million | $17.899 million | $4.792 million quarter; $10.832 million half-year |
| Net loss | $10.901 million | $17.612 million | $4.750 million quarter; $11.162 million half-year |
| Basic and diluted loss per share | $0.63 | $1.02 | $0.44 quarter; $1.04 half-year |
| Cash used in operating activities | Not presented separately for the quarter | $13.788 million | $11.699 million half-year |
Margins are not meaningful because the company had no revenue. For the six months, other income was $287,000, compared with other expense of $330,000 in 2015; the 2016 amount included $249,000 of interest income.
Liquidity, debt and balance sheet
At June 30, 2016, cash and cash equivalents were $22.470 million, short-term investments $44.089 million and long-term investments $32.664 million, totaling approximately $99.2 million in cash and investments. Working capital was $59.2 million. Total assets were $100.7 million and total liabilities $8.6 million. The filing reports no outstanding bank loan: the SVB loan had been repaid in 2014. Other liabilities included a $7,000 capital lease obligation and a $51,000 warrant liability. Management said existing resources were expected to fund operations for at least 12 months, while also anticipating a need for substantial future financing.
Six-month investing cash use was $3.302 million, primarily reflecting net investment purchases; financing cash provided was $3,000. Cash and cash equivalents decreased by $17.056 million during the half-year.
Material changes and management commentary
- First-half net loss increased to $17.6 million from $11.2 million, principally as research and development spending rose while the company advanced IC/BPS development.
- R&D expense included accrual of a $2.3 million (CAD $3.0 million) milestone payment to Biolipox. A further CAD $1.5 million of milestone payments could be due upon first commercial sale in the United States, Europe or Japan.
- G&A expense increased, primarily due to higher personnel costs and establishing a San Bruno, California office.
- Cash, cash equivalents and investments declined from approximately $112.9 million at December 31, 2015 to $99.2 million at June 30, 2016.
Outlook, risks and unusual items
- Aquinox expected its Leadership 301 Phase 3 IC/BPS trial to commence in the third quarter of 2016. It had submitted the proposed protocol to the FDA in May and was preparing submissions to European health authorities. FDA and EMA advice included potential additional clinical, preclinical and manufacturing work.
- The company expected R&D spending to increase as clinical development progressed. Future capital needs could require equity or debt financing, strategic arrangements or licensing; additional financing might not be available on acceptable terms and could dilute shareholders or constrain operations.
- Prior Phase 2 results were mixed: Leadership 201 showed a positive trend on its primary endpoint but did not achieve statistical significance on that endpoint; Flagship (COPD) and Kinship (atopic dermatitis) failed to demonstrate efficacy. The company was not planning further development in those two indications.
- Key risks include the unvalidated SHIP1 target, clinical and regulatory uncertainty, dependence on AQX-1125 and third-party research and manufacturing providers, and potential additional trial requirements. Animal studies reported severe gastrointestinal ulcerations in dogs and ocular-lens effects in some animals; clinical trials most commonly reported mild gastrointestinal effects.
- The company disclosed no off-balance-sheet arrangements and no material change in contractual commitments from its 2015 Form 10-K. It did not hedge foreign-currency exposure; management estimated a hypothetical 100-basis-point rate increase would reduce investment portfolio fair value by $0.6 million.
Important facts for investors to verify
- Confirm the intended issuer: this filing names Aquinox Pharmaceuticals, Inc., not Neurogene Inc.
- Check subsequent disclosures for Leadership 301’s actual start date, enrollment, design and results, and any additional FDA or EMA requirements.
- Assess cash burn and financing needs against the stated minimum 12-month runway, including clinical costs and milestone obligations.
- Review later evidence on AQX-1125’s efficacy and safety, given the mixed prior Phase 2 results and the unsuccessful COPD and atopic dermatitis trials.
- Verify the status and terms of any subsequent financing, collaboration, licensing arrangement or material change in the Biolipox obligations.